NYSE: TAK

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that China’s National Medical Products Administration...

Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Fineline Cube Aug 6, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the U.S. Food and Drug...

Company

Takeda Reports Q1 FY2026 Revenue of JPY 1.22 Trillion, Outlines Growth Strategy Centered on Three Key Pipeline Assets

Fineline Cube Aug 6, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) released its financial results for the first...

Company Drug

Takeda Secures World’s First NMPA Approval for Orexatone – Novel Oral OX2R Agonist for Type 1 Narcolepsy

Fineline Cube Jul 23, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that China’s National Medical Products Administration...

Company Deals

Takeda and Indonesian Government Launch $30 Million Plasma Ecosystem Initiative to Expand Access to Lifesaving Therapies

Fineline Cube Jul 13, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) and the Indonesian Government announced a groundbreaking...

Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026

Insilico Medicine (HKG: 3696) announced a strategic collaboration agreement with Takeda Pharmaceutical Company Limited (TYO:...

Company Drug

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

Fineline Cube Jun 25, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that China’s National Medical Products Administration...

Company Drug

Takeda’s Zasocitinib Demonstrates Superior Efficacy Over Deucravacitinib in Phase III Psoriasis Trial with 35% PASI 100 Response Rate

Fineline Cube Jun 12, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced positive topline results from a Phase...

Company Drug

Takeda’s Entyvio Receives FDA Acceptance for Pediatric sBLA in Ulcerative Colitis and Crohn’s Disease, Expanding Gut-Selective Biologic to Patients Aged 2+

Fineline Cube Jun 10, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the U.S. Food and Drug...

Others

Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law

Fineline Cube May 20, 2026

A federal jury in the U.S. District Court for the District of Massachusetts returned a...

Company

Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan

Fineline Cube May 14, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) reported fiscal year 2025 financial results with...

Company Deals

Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment

Fineline Cube Apr 8, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced the termination of its neuroscience collaboration...

Company Drug

Takeda’s Zasocitinib Demonstrates Superior Efficacy Over Apremilast and Placebo in Phase III Psoriasis Trials with Unprecedented TYK2 Selectivity

Fineline Cube Mar 30, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) reported positive top-line results from two pivotal...

Company Drug

Takeda’s Oveporexton Wins FDA Priority Review for Narcolepsy Type 1, Potential First Orexin Agonist

Fineline Cube Feb 11, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced that the U.S. Food and Drug Administration (FDA)...

Company Deals Digital

Takeda Enters $1.7 Billion AI Drug Discovery Partnership with Iambic Therapeutics

Fineline Cube Feb 11, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) has entered a multi-year strategic agreement with Iambic Therapeutics,...

Company Deals

Takeda Ends $128M Kyoto University iPSC Project After Decade of Research

Fineline Cube Feb 5, 2026

Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) announced the termination of its ten‑year induced pluripotent stem cell (iPSC)...

Company

Takeda Q3 Revenue Drops 3.3% on VYVANSE Generics, Raises Full-Year Forecast

Fineline Cube Jan 30, 2026

Takeda Pharmaceutical Co. (TYO: 4502, NYSE: TAK) reported third‑quarter fiscal 2025 revenue of 3,411.2 billion yen (USD 22.17 billion), down...

Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Fineline Cube Jan 11, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced a global collaboration and license agreement...

Company Drug

Takeda and Protagonist Submit Rusfertide NDA for Polycythemia Vera

Fineline Cube Jan 7, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) and Protagonist Therapeutics, Inc. (NASDAQ: PTGX) announced...

Company Drug

Takeda Zasocitinib TYK2 Phase III Shows Positive Psoriasis Results

Fineline Cube Dec 23, 2025

Takeda Pharmaceutical Company (TYO: 4502, NYSE: TAK) announced positive topline results from two pivotal Phase III...

NYSE: TAK

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Takeda Reports Q1 FY2026 Revenue of JPY 1.22 Trillion, Outlines Growth Strategy Centered on Three Key Pipeline Assets

Takeda Secures World’s First NMPA Approval for Orexatone – Novel Oral OX2R Agonist for Type 1 Narcolepsy

Takeda and Indonesian Government Launch $30 Million Plasma Ecosystem Initiative to Expand Access to Lifesaving Therapies

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

Takeda’s Zasocitinib Demonstrates Superior Efficacy Over Deucravacitinib in Phase III Psoriasis Trial with 35% PASI 100 Response Rate

Takeda’s Entyvio Receives FDA Acceptance for Pediatric sBLA in Ulcerative Colitis and Crohn’s Disease, Expanding Gut-Selective Biologic to Patients Aged 2+

Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law

Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan

Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment

Takeda’s Zasocitinib Demonstrates Superior Efficacy Over Apremilast and Placebo in Phase III Psoriasis Trials with Unprecedented TYK2 Selectivity

Takeda’s Oveporexton Wins FDA Priority Review for Narcolepsy Type 1, Potential First Orexin Agonist

Takeda Enters $1.7 Billion AI Drug Discovery Partnership with Iambic Therapeutics

Takeda Ends $128M Kyoto University iPSC Project After Decade of Research

Takeda Q3 Revenue Drops 3.3% on VYVANSE Generics, Raises Full-Year Forecast

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Takeda and Protagonist Submit Rusfertide NDA for Polycythemia Vera

Takeda Zasocitinib TYK2 Phase III Shows Positive Psoriasis Results

You Missed

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis